炎症性肠病非侵入生物标志物的研究进展
Research progress on non-invasive biomarkers for inflammatory bowel disease
胡帅 1谢军2
作者信息
- 1. 赣南医科大学第一临床医学院
- 2. 赣南医科大学第一附属医院消化内科,江西 赣州 341000
- 折叠
摘要
炎症性肠病(Inflammatory bowel disease,IBD)是一组慢性非特异性炎症性肠道疾病,主要包括克罗恩病和溃疡性结肠炎.IBD的病因尚不完全明确,但被认为是遗传易感个体中环境因素、微生物、感染及免疫反应等多重因素交互作用的结果.目前内镜和病理学检查仍是常用的监测手段,但由于其是侵入性检测且价格昂贵,就医体验降低等不易被患者接受.近年来无创性生物标志物的研究为评估IBD患者的疾病状态和治疗效果提供了新的可能性.本文综述了血液、粪便和体液中的无创性生物标志物在IBD疾病诊疗中的应用潜力.在减少侵入性检测、优化个性化治疗策略以及早期识别疾病活动和缓解状态方面,通过综合应用这些生物标志物与临床参数,可以更加准确地评估患者疾病状态,调整治疗策略,为IBD患者提供更精细化、个体化的治疗,改善患者的预后和生活质量.
Abstract
Inflammatory bowel disease(IBD)is a group of chronic nonspecific inflammatory bowel diseases,mainly including Crohn's disease(CD)and ulcerative colitis(UC).The etiology of IBD is not fully understood,but it is thought to be a result of the interaction of multiple factors such as environmental factors,microorganisms,infections,and immune responses in genetically susceptible individuals.Endoscopy and pathology are still commonly used for surveillance,but they are not easily accepted by patients because they are invasive tests,expensive,and the healthcare experience is reduced.Recent studies of noninvasive biomarkers have provided new possibilities for assessing disease status and treatment outcomes in patients with IBD.In this paper,we comprehensively discuss the potential application of noninvasive biomarkers in blood,feces,and body fluids in IBD disease management,especially in reducing invasive testing,optimizing personalized treatment strategies,and identifying disease activity and remission status at an early stage.By integrating the application of these biomarkers with clinical parameters,we can more accurately assess the disease status of the patients,adjust the therapeutic strategies,provide IBD patients with more refined and individualized treatment,and improve the prognosis and quality of life of patients.
关键词
炎症性肠病/生物标志物/诊断/粪便钙卫蛋白/微核糖核酸Key words
Inflammatory bowel disease/Biomarkers/Diagnose/Fecal calprotectin/MicroRNA引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据